VRTX · Vertex Pharmaceuticals Inc · Webcasts, Transcripts & Audio
$538.60
-4.02 (-0.74%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$136.56B
Shares
253.54M
Volume · Nov 13
757.93K
Avg daily vol (3M)
1.24M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Vertex Pharmaceuticals Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Vertex Pharmaceuticals Inc (VRTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-02
Vertex Pharmaceuticals Inc (VRTX) Q3 2026 Earnings Call Transcript
Confident tone
POVI renal launch
Crenetics acquisition and Palsanify integration
CF franchise and Eliftrek expansion
Revenue
$3.44B
▲ 11.8% YoY Diluted EPS
$2.56
▼ 39% YoY Gross margin
84.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-10-24
Vertex Pharmaceuticals Inc (VRTX) October 24, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-23
Vertex Pharmaceuticals Inc (VRTX) September 23, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Vertex Pharmaceuticals Inc (VRTX) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Vertex Pharmaceuticals Inc (VRTX) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-03
Vertex Pharmaceuticals Inc (VRTX) Q2 2026 Earnings Call Transcript
Confident tone
Cystic Fibrosis Franchise
DM1 Program
Regulatory Milestones
Revenue
$3.33B
▲ 12.5% YoY Diluted EPS
$4.31
▲ 8% YoY Gross margin
85.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-07-06
Vertex Pharmaceuticals Inc (VRTX) July 6, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-10
Vertex Pharmaceuticals Inc (VRTX) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-10
Vertex Pharmaceuticals Inc (VRTX) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-29
Vertex Pharmaceuticals Inc (VRTX) May 29, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-29
Vertex Pharmaceuticals Inc (VRTX) May 29, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Vertex Pharmaceuticals Inc (VRTX) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Vertex Pharmaceuticals Inc (VRTX) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Vertex Pharmaceuticals Inc (VRTX) Q1 2026 Earnings Call Transcript
Confident tone
Renal franchise / POVI (povetacicept)
Cystic Fibrosis franchise (Trikafta/Aliftrek)
Inaxaplin AMKD program
Revenue
$2.99B
▲ 7.8% YoY Diluted EPS
$4.02
▲ 61.4% YoY Gross margin
86.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Vertex Pharmaceuticals Inc (VRTX) March 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-12
Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Transcript
Confident tone
Renal franchise and Povetacicept (POVI)
Clinical trial readouts and DSMB / Rainier study
Financial guidance and 2026 outlook
Revenue
$3.19B*
▲ 9.5% YoY Gross margin
85.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Vertex Pharmaceuticals Inc (VRTX) Q3 2025 Earnings Call Transcript
Confident tone
Cystic Fibrosis Franchise and ALYFTREK Uptake
Pain Portfolio (JOURNAVX in Acute and Neuropathic Pain)
Renal Pipeline (Povetacicept, Inaxaplin, VX-407)
Revenue
$3.08B
▲ 11% YoY Diluted EPS
$4.20
▲ 4.7% YoY Gross margin
86.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Transcript
Confident tone
JOURNAVX (acute pain) launch and access
CF franchise and ALYFTREK launch
CASGEVY cell therapy momentum
Revenue
$2.96B
▲ 12.1% YoY Diluted EPS
$3.99
Gross margin
86.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Vertex Pharmaceuticals Inc (VRTX) Q1 2025 Earnings Call Transcript
Revenue
$2.77B
▲ 3% YoY Diluted EPS
$2.49
▼ 40.9% YoY Gross margin
86.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-10
Vertex Pharmaceuticals Inc (VRTX) Q4 2024 Earnings Call Transcript
Confident tone
JOURNAVX (suzetrigine) launch in acute pain
Cystic Fibrosis franchise performance and ALYFTREK launch
CASGEVY launch in sickle cell disease and beta thalassemia
Revenue
$2.91B*
▲ 15.7% YoY Gross margin
85.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Transcript
Confident tone
Suzetrigine (VX-548) in acute pain and access
CASGEVY launch in sickle cell disease and beta thalassemia
Povetacicept in IgA nephropathy and broader autoimmune
Revenue
$2.77B
▲ 11.6% YoY Diluted EPS
$4.01
▲ 1% YoY Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Vertex Pharmaceuticals Inc (VRTX) Q2 2024 Earnings Call Transcript
Confident tone
Suzetrigine acute pain launch
Cystic Fibrosis (Vanzacaftor Triple launch)
CASGEVI launch (sickle cell / beta-thalassemia)
Revenue
$2.65B
▲ 6.1% YoY Diluted EPS
$-13.92
▼ 495.5% YoY Gross margin
85.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Vertex Pharmaceuticals Inc (VRTX) Q1 2024 Earnings Call Transcript
Confident tone
Suzetrigine acute pain NDA and launch readiness
CASGEVY launch in sickle cell disease and beta thalassemia
Alpine Immune Sciences acquisition and povetacicept
Revenue
$2.69B
▲ 13.3% YoY Diluted EPS
$4.21
▲ 56.5% YoY Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-05
Vertex Pharmaceuticals Inc (VRTX) Q4 2023 Earnings Call Transcript
Confident tone
Cystic Fibrosis / vanzacaftor triple (vanza)
Acute pain program VX-548
Pipeline expansion into new disease areas
Revenue
$2.52B*
▲ 9.3% YoY Gross margin
85.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Vertex Pharmaceuticals Inc (VRTX) Q3 2023 Earnings Call Transcript
Revenue
$2.48B
▲ 6.4% YoY Diluted EPS
$3.97
▲ 10.6% YoY Gross margin
87.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Vertex Pharmaceuticals Inc (VRTX) Q2 2023 Earnings Call Transcript
Revenue
$2.49B
▲ 13.5% YoY Diluted EPS
$3.52
▲ 12.5% YoY Gross margin
87.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-01
Vertex Pharmaceuticals Inc (VRTX) Q1 2023 Earnings Call Transcript
Revenue
$2.37B
▲ 13.2% YoY Diluted EPS
$2.69
▼ 9.1% YoY Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-07
Vertex Pharmaceuticals Inc (VRTX) Q4 2022 Earnings Call Transcript
Revenue
$2.30B*
▲ 11.1% YoY Gross margin
87.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Vertex Pharmaceuticals Inc (VRTX) Q3 2022 Earnings Call Transcript
Revenue
$2.33B
▲ 17.7% YoY Diluted EPS
$3.59
▲ 9.5% YoY Gross margin
87.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Vertex Pharmaceuticals Inc (VRTX) Q2 2022 Earnings Call Transcript
Revenue
$2.20B
▲ 22.5% YoY Diluted EPS
$3.13
▲ 1103.8% YoY Gross margin
88.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Vertex Pharmaceuticals Inc (VRTX) Q1 2022 Earnings Call Transcript
Revenue
$2.10B
▲ 21.6% YoY Diluted EPS
$2.96
▲ 18.9% YoY Gross margin
88.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-26
Vertex Pharmaceuticals Inc (VRTX) Q4 2021 Earnings Call Transcript
Revenue
$2.07B*
▲ 27.3% YoY Gross margin
88.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Vertex Pharmaceuticals Inc (VRTX) Q3 2021 Earnings Call Transcript
Revenue
$1.98B
▲ 29% YoY Diluted EPS
$3.28
▲ 29.6% YoY Gross margin
88.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Vertex Pharmaceuticals Inc (VRTX) Q2 2021 Earnings Call Transcript
Revenue
$1.79B
▲ 17.6% YoY Diluted EPS
$0.26
▼ 91.8% YoY Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript
Revenue
$1.72B
▲ 13.8% YoY Diluted EPS
$2.49
▲ 8.7% YoY Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-01
Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript
Revenue
$1.63B
▲ 15.2% YoY Diluted EPS
$2.30
▲ 3.1% YoY Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Vertex Pharmaceuticals Inc (VRTX) Q3 2020 Earnings Call Transcript
Revenue
$1.54B
▲ 62% YoY Diluted EPS
$2.53
▲ 1050% YoY Gross margin
87.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Vertex Pharmaceuticals Inc (VRTX) Q2 2020 Earnings Call Transcript
Revenue
$1.52B
▲ 62% YoY Diluted EPS
$3.18
▲ 208.7% YoY Gross margin
87.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Vertex Pharmaceuticals Inc (VRTX) Q1 2020 Earnings Call Transcript
Revenue
$1.52B
▲ 76.5% YoY Diluted EPS
$2.29
▲ 122.3% YoY Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call
Revenue
$1.41B
▲ 62.4% YoY Diluted EPS
$2.23
▼ 62.6% YoY Gross margin
86.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–40 of 40 webcasts
Key facts
CIK
875320
CUSIP
92532F100
13F (30d)
1437 filings
1358 filers
Visit website
Investor relations